The Immune System
Under Control
Our Company
AbolerIS Pharma is a Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.
Lead Program
AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system.
Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.
Latest updates
Nantes, France, November 22, 2022 – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune…
-Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B cells,…
GOSSELIES, Belgium and NANTES, France, April 24, 2025 -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of…